June 11, 2018 10:24 AM EDT

BridgeBio bags Alexion's ultra-rare disease asset; Allergan touts a new set of late-stage data for oral CGRP drug

John Carroll

Editor & Founder

→ Startup factory BridgeBio has snatched an asset from Alexion, set it up under a new company called Origin Biosciences, and funded its operations. The …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

BridgeBio bags Alexion's ultra-rare disease asset; Allergan touts a new set of late-stage data for oral CGRP drug

John Carroll

Editor & Founder

Sign up to read this article for free.

CagriSema’s weight loss data disappointed. What does Novo do next?

FDA approves Lilly's Zepbound for sleep apnea, likely cracking open Medicare market

Vertex gets 'vanza triple' approval and Trikafta expansion — with boxed warnings

Bristol Myers' TYK2 inhibitor succeeds in pair of Phase 3 psoriatic arthritis trials

Novo Nordisk’s once-daily hemophilia drug Alhemo approved in US

Jim Wilson's GemmaBio raises $34M to commercialize gene therapies for rare diseases

Bridge­Bio bags Alex­ion's ul­tra-rare dis­ease as­set; Al­ler­gan touts a new set of late-stage da­ta for oral CGRP drug

John Carroll

Editor & Founder

Sign up to read this article for free.

more like this

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

Bris­tol My­er­s' TYK2 in­hibitor suc­ceeds in pair of Phase 3 pso­ri­at­ic arthri­tis tri­als

No­vo Nordisk’s once-dai­ly he­mo­phil­ia drug Al­he­mo ap­proved in US

Jim Wilson's Gem­ma­Bio rais­es $34M to com­mer­cial­ize gene ther­a­pies for rare dis­eases

BridgeBio bags Alexion's ultra-rare disease asset; Allergan touts a new set of late-stage data for oral CGRP drug

CagriSema’s weight loss data disappointed. What does Novo do next?

FDA approves Lilly's Zepbound for sleep apnea, likely cracking open Medicare market

Vertex gets 'vanza triple' approval and Trikafta expansion — with boxed warnings

Bristol Myers' TYK2 inhibitor succeeds in pair of Phase 3 psoriatic arthritis trials

Novo Nordisk’s once-daily hemophilia drug Alhemo approved in US

Jim Wilson's GemmaBio raises $34M to commercialize gene therapies for rare diseases